Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.
Ambulatory bloodstream infections in pediatric oncology and stem cell transplant patients result in significant health care charges and extended hospital admissions.
Blood stem cells derived from donor bone marrow resulted in better self-reported psychological well-being and fewer GVHD symptoms.
Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.
Bone marrow transplantation can be improved by optimizing the dose of transplanted hematopoietic stem cells, according to recent results from a mouse model.
Incidence of frailty among young survivors of bone marrow transplant is similar to that of the elderly population, and increases the risk of death compared with nonfrail survivors.
High-risk medications can increase falls in patients undergoing treatment for malignant hematology, but implementing risk-specific fall prevention strategies can ameliorate the effects of the drugs.
Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical TransplantationApril 25, 2016
Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.
How is loratadine used to treat bone pain in patients receiving white blood cell growth factors?
A calculator for determining Expected PCO2 (Winters).
Survey Shows Clinician Opinions on Timing of End-of-life Discussions for Patients With Blood CancersJanuary 04, 2016
In a survey on end-of-life (EOL) discussions, hematologic oncologists reported that these discussions with patients who have blood cancers occur too late, according to a recent report.
High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With AmyloidosisOctober 27, 2015
Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.
Implementing proactive telephone support reduced unplanned hospitalizations among patients with blood cancers by 70%.
DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be effective in a small group of patients with relapsed/refractory B-cell malignancies, according to clinical trial results.
Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
The use of chimeric antigen receptor (CAR) cell engineering was described in several studies presented at the 2013 ASH Annual Meeting in New Orleans.
T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.
The risk of developing therapy-related acute myeloid leukemia after chemotherapy varies depending on initial cancer and treatment practices.
Older patients may not respond as well as younger persons to conventional therapies for chronic lymphocytic leukemia, a new study indicates.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
A round-up of some of the top developments in hematology and oncology in December 2012.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
ONS Connections: Reliable biomarker for central nervous system tissue injury during pediatric leukemia treatmentNovember 19, 2012
During the post-induction phase of treatment for childhood acute lymphoblastic leukemia (ALL), F2 isoprostanes significantly increase, allowing central nervous system (CNS) tissue injury to be monitored.
Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).
A novel method has been developed to determine how ready acute myeloid leukemia (AML) cells are to die. This discovery may help to more effectively choose treatment options for patient with AML.
Flow cytometry has been identified as better for checking for minimal residual disease than two other widely used methods to predict patient survival.
A roundup of the top hematology and oncology news in August 2012.
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- 3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma
- Lung Cancer Navigator App Aims to Help Patients Understand Disease
- Racial Disparities Persist in Myeloma Treatment Use
- Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy
- Frailty Classifications Associated With Prognosis Among Older Patients
- Beach Umbrella Not Enough for Protection from UV Rays
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- ASCO: Moderate Activity Linked to Longer Survival in Advanced CRC
- MABp1 Improves Symptoms vs Placebo in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|